NCI CTEP-Approved Trials for the Month of April
Researchers at UC Davis have shown that radiation therapy following surgery benefits older patients more than younger patients when treating soft tissue sarcomas.
A five-year study showed that stereotactic body radiation therapy to treat prostate cancer offers a higher cure rate than more traditional approaches, according to researchers at UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center.
Overall survival data from CheckMate-069, a phase II trial of a Opdivo and Yervoy combination regimen in patients with previously untreated advanced melanoma, demonstrated a two-year overall survival rate of 69 percent compared to 53 percent for Yervoy alone (HR=0.58 [95% CI: 0.31-1.08]) in patients with BRAF wild-type advanced melanoma.
A phase III trial of farletuzumab failed to meet its endpoints of significantly increasing progression-free survival or overall survival in ovarian cancer patients.
A phase III trial of PD-1 inhibitor Opdivo showed significant survival benefit at one year—compared to investigator's choice of methotrexate, docetaxel or cetuximab—in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
FDA approved Gilotrif (afatinib) tablets for the treatment of patients with advanced squamous cell carcinoma of the lung whose disease has progressed after treatment with platinum-based chemotherapy.
The University of Chicago and AbbVie entered into a five-year collaboration in oncology. Initially, both organizations will work together to advance research in several areas of oncology, which could include, among others, breast, lung, prostate, colorectal and hematological cancer. Research projects are chosen by a joint steering committee, comprised of representatives from each organization. AbbVie... […]
NIH has suspended the facilities that produce investigational compounds for an NCI laboratory engaged in cell therapy production and a National Institute of Mental Health facility producing positron emission tomography materials.
The NCI Board of Scientific Advisors approved a proposal to expand the infrastructure and capacity of the SEER program, including introducing registries designed specifically to support cancer research projects, an increase of the program's overall budget, and moving toward a more advanced, uniform data management system.
